The study looked at how well a hormone-releasing IUD works for treating thickened uterine lining (endometrial hyperplasia) in Chinese women. It found high cure rates, especially after a year, and few side effects, but the research is specific to a medical condition that isn’t relevant to most biohackers.

<b>Objective:</b> To systematically evaluate the efficacy and safety of the levonorgestrel-releasing intrauterine system (LNG-IUS) in patients with endometrial hyperplasia (EH). <b>Methods:</b> PubMed, Embase, the Cochrane Library, CNKI, Wanfang, CBM, and VIP were searched from inception to January 2023 for clinical trials or cohort studies involving Chinese EH patients treated with LNG-IUS alone or in combination. After screening the eligible studies, data on study population characteristics, efficacy, and safety indicators were extracted and analyzed. <b>Results:</b> A total of 141 studies involving 12 919 Chinese patients diagnosed with EH were included, of which 92 were randomized controlled trial (RCT) and 49 were cohort studies. The systematic review showed that after 3-12 months of LNG-IUS monotherapy, the complete response (CR) rates among Chinese patients with atypical endometrial hyperplasia (AEH) and non-atypical endometrial hyperplasia (NAEH) were 36.0%-92.3% and 23.9%-100.0%, respectively. After 12 months of treatment, the CR rate reached 84.2%-93.3%. Compared with oral progestin (OP) therapy, the CR rate after 3-12 months of LNG-IUS monotherapy was 43.6%-100.0%, while that for OP was 26.7%-97.5%. The CR rate among EH patients receiving LNG-IUS combined with gonadotropin-releasing hormone agonist (GnRHa) for 3-6 months was 31.3%-100.0%, and that for those receiving LNG-IUS combined with OP was 33.3%-93.8%. In regimens combining LNG-IUS with other drugs, LNG-IUS did not increase the incidence of adverse events (&#x2264;7.1%). <b>Conclusion:</b> LNG-IUS is a feasible and effective treatment option for Chinese patients with EH, offering high tolerability and low safety risks.